XML 52 R42.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Collaboration and License Agreements - Additional Information (Detail) (USD $) | 3 Months Ended | 9 Months Ended |  | 3 Months Ended | 9 Months Ended |  | 3 Months Ended | 9 Months Ended |  | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 3 Months Ended | 9 Months Ended |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | Sep. 30, 2013 Les Laboratoires Servier [Member] | Sep. 30, 2012 Les Laboratoires Servier [Member] | Sep. 30, 2013 Les Laboratoires Servier [Member] | Sep. 30, 2012 Les Laboratoires Servier [Member] | Dec. 31, 2012 Les Laboratoires Servier [Member] | Sep. 30, 2013 Les Laboratoires Servier [Member] Second Right to Develop Collaboration [Member] | Sep. 30, 2012 Les Laboratoires Servier [Member] Second Right to Develop Collaboration [Member] | Sep. 30, 2013 Les Laboratoires Servier [Member] Second Right to Develop Collaboration [Member] | Sep. 30, 2012 Les Laboratoires Servier [Member] Second Right to Develop Collaboration [Member] | Dec. 31, 2012 Les Laboratoires Servier [Member] Second Right to Develop Collaboration [Member] | Sep. 30, 2013 Gilead [Member] | Sep. 30, 2013 Gilead [Member] Molecule Program | Sep. 30, 2013 Boehringer [Member] | Sep. 30, 2012 Boehringer [Member] | Sep. 30, 2013 Boehringer [Member] Molecule Payments | Sep. 30, 2012 Boehringer [Member] | Dec. 31, 2012 Boehringer [Member] | Jan. 31, 2011 Boehringer [Member] Series D-2 Convertible Preferred Stock [Member] | Oct. 31, 2010 Pfizer [Member] Molecule | Sep. 30, 2013 Pfizer [Member] | Sep. 30, 2012 Pfizer [Member] | Sep. 30, 2013 Pfizer [Member] Program | Sep. 30, 2012 Pfizer [Member] | Dec. 31, 2012 Pfizer [Member] | Sep. 30, 2013 Green Cross Corporation [Member] | Sep. 30, 2012 Green Cross Corporation [Member] | Sep. 30, 2013 Green Cross Corporation [Member] | Sep. 30, 2012 Green Cross Corporation [Member] | Dec. 31, 2012 Green Cross Corporation [Member] | Oct. 28, 2010 Eli Lilly [Member] | May 31, 2008 Eli Lilly [Member] | Sep. 30, 2013 Eli Lilly [Member] | Sep. 30, 2012 Eli Lilly [Member] | Sep. 30, 2013 Eli Lilly [Member] | Sep. 30, 2012 Eli Lilly [Member] | Dec. 31, 2012 Eli Lilly [Member]
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement date |  |  |  |  |  |  |  | November 2011 |  |  |  |  | September 2012 |  |  |  | January 2013 |  |  | October 2010 |  |  |  | October 2010 |  |  |  |  |  |  |  | June 2010 |  |  |  |  |  |  | October 2007 |  |
Non-refundable upfront payment |  |  |  |  |  |  |  | $ 20,000,000 |  |  |  |  | $ 20,000,000 |  |  |  |  |  |  | $ 15,000,000 |  |  |  | $ 5,000,000 |  |  | $ 5,000,000 |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  | $ 41,000,000 |  |
License grant fees |  |  |  |  |  | 30,000,000 |  | 30,000,000 |  |  | 65,000,000 |  | 65,000,000 |  |  | 7,500,000 | 7,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical milestone payments |  |  |  |  |  |  |  | 47,000,000 |  |  |  |  | 98,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone payments |  |  |  |  |  | 140,000,000 |  | 140,000,000 |  |  | 300,000,000 |  | 300,000,000 |  |  | 355,000,000 | 355,000,000 | 89,000,000 |  | 89,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales milestone payments |  |  |  |  |  |  |  | 208,000,000 |  |  |  |  | 630,000,000 |  |  |  | 500,000,000 |  |  | 83,000,000 |  |  |  |  |  |  | 195,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected period of development |  |  |  |  |  |  |  | 27 months |  |  |  |  | 29 months |  |  |  | 21 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Recognized revenue under agreement | 20,111,173 | 15,532,680 | 42,015,994 | 50,283,510 |  | 12,300,000 | 2,300,000 | 18,900,000 | 6,800,000 |  | 2,200,000 | 0 | 6,500,000 | 0 |  | 2,200,000 | 5,900,000 | 2,300,000 | 2,500,000 | 6,900,000 | 9,300,000 |  |  |  | 900,000 | 1,200,000 | 3,200,000 | 4,000,000 |  | 25,000 | 25,000 | 75,000 | 75,000 |  |  |  | 190,833.0 | 9,500,000 | 673,927.0 | 30,100,000 |
Milestone payment |  |  |  |  |  | 10,000,000 |  | 10,000,000 |  |  |  |  |  |  |  |  |  |  |  | 41,000,000 |  | 2,000,000 |  |  |  |  |  |  | 500,000 |  |  |  |  |  |  | 50,000,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  | 3,100,000 |  | 3,100,000 |  | 10,000,000 | 11,600,000 |  | 11,600,000 |  | 18,000,000 |  |  | 10,300,000 |  | 10,300,000 |  | 14,000,000 |  |  |  |  |  |  |  | 675,000 |  | 675,000 |  | 750,000 |  |  |  |  |  |  |
Deferred revenue included in current liabilities | 21,298,318 |  | 21,298,318 |  | 24,123,176 |  |  |  |  | 9,100,000 | 8,600,000 |  | 8,600,000 |  | 8,600,000 | 4,400,000 | 4,400,000 | 5,000,000 |  | 5,000,000 |  | 5,000,000 |  |  | 58,000,000,000 |  | 58,000,000,000 |  | 1,300,000 | 100,000 |  | 100,000 |  | 100,000 |  |  |  |  |  |  |
Deferred revenue included in long-term liabilities | 8,812,342 |  | 8,812,342 |  | 19,956,343 |  |  |  |  | 900,000 | 3,000,000 |  | 3,000,000 |  | 9,400,000 |  |  | 5,300,000 |  | 5,300,000 |  | 9,000,000 |  |  |  |  |  |  |  | 575,000 |  | 575,000 |  | 650,000 |  |  |  |  |  |  |
Clinical milestone payments under agreement |  |  |  |  |  |  |  |  |  |  | 5,000,000 |  | 5,000,000 |  |  | 200,000,000 | 200,000,000 |  |  |  |  |  |  |  | 17,000,000 |  | 17,000,000 |  |  | 4,500,000 |  | 4,500,000 |  |  |  |  |  |  |  |  |
Commercialization of molecules |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 |  |  | 10 |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Molecules having exclusive worldwide rights |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of programs Company retains development and commercialization rights outside |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional license grant fees |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 22,500,000 | 22,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivables | 2,281,282 |  | 2,281,282 |  | 2,046,219 |  |  |  |  |  |  |  |  |  |  | 1,100,000 | 1,100,000 | 246,375 |  | 246,375 |  | 355,568 |  |  | 501,794 |  | 501,794 |  | 896,285 |  |  |  |  |  |  |  | 244,542 |  | 244,542 |  | 558,516
Number of annual maintenance payments received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received including upfront, annual maintenance and milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 39,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preferred Stock purchased |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research obligation completion date |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2015-09 |  |  |  |  |  |  | 2014-01 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period of agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
DART program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Term of the agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2020-06 |  |  |  |  |  |  |  |  |
Review of clinical data |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 year |  |  |  |  |  |

X
- Definition Aggregate potential remaining clinical milestone payments available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional payment under licensing and collaboration agreement. + References No definition available. + Details
Name: | mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate potential remaining regulatory milestone payments available to be earned under a collaboration arrangement. + References No definition available. + Details
Name: | mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Clinical data review period for agreement termination. + References No definition available. + Details
Name: | mgnx_ClinicalDataReviewPeriodForAgreementTermination
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Clinical development milestone payments received. + References No definition available. + Details
Name: | mgnx_ClinicalDevelopmentMilestonePaymentsReceived
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration and license agreement entered date. + References No definition available. + Details
Name: | mgnx_CollaborationAndLicenseAgreementEnteredDate
Namespace Prefix: | mgnx_
Data Type: | us-types:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative agreement period of contract. + References No definition available. + Details
Name: | mgnx_CollaborativeAgreementPeriodOfContract
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | mgnx_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | mgnx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate potential remaining license grant fee payments available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_LicenseGrantFeesReceivable
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Initial fee received from collaboration or license agreement. + References No definition available. + Details
Name: | mgnx_NonRefundableFees
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of annual maintenance payment received. + References No definition available. + Details
Name: | mgnx_NumberOfAnnualMaintenancePaymentReceived
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of programs for which collaborator has worldwide rights. + References No definition available. + Details
Name: | mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of molecules to be developed and commercialized as per collaborations. + References No definition available. + Details
Name: | mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of programs. + References No definition available. + Details
Name: | mgnx_NumberOfPrograms
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of programs for which company retains development and commercialization rights in certain countries. + References No definition available. + Details
Name: | mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total cumulative payments received to date under collaboration agreement. + References No definition available. + Details
Name: | mgnx_PaymentReceivedOnCollaborationAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research obligation completion date. + References No definition available. + Details
Name: | mgnx_ResearchObligationCompletionDate
Namespace Prefix: | mgnx_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate potential remaining sales milestone payments available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_SalesMilestonePayments
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront fee and participation recognition date. + References No definition available. + Details
Name: | mgnx_UpfrontFeeAndParticipationRecognitionDate
Namespace Prefix: | mgnx_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment recognition period. + References No definition available. + Details
Name: | mgnx_UpfrontPaymentRecognitionPeriod
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration